Cryoport, Inc. provides temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. The Company supports biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products. Its integrated supply chain platform includes the Cryoportal Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems. The Company's segments include Life Sciences Services and Life Sciences Products. The Company's Life Sciences Services segment provides cryogenic biostorage within the life science industry through direct sales. Its Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PB is 1.77, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 49.22M shares, decreasing 18.53% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 25.00K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.66.